Larvol Veri

BIOMARKER:

ER positive

Entrez ID:

2099

Related biomarkers:

‹

›

ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials ESMO-BC 2021 - 5 days palbociclib Sensitive : B ESMO-BC 2021 - 5d
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	letrozole Sensitive: C2 – Inclusion Criteria ESMO-BC 2021 - 5 days letrozole Sensitive : C2 ESMO-BC 2021 - 5d
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ribociclib Sensitive: C2 – Inclusion Criteria ESMO-BC 2021 - 5 days ribociclib Sensitive : C2 ESMO-BC 2021 - 5d
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen + TAK-228 Sensitive: C2 – Inclusion Criteria Breast Cancer Res Treat - 3 weeks tamoxifen + TAK-228 Sensitive : C2 Breast Cancer Res Treat - 3wk
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval fulvestrant Sensitive : A1
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	exemestane Sensitive: A1 - Approval exemestane Sensitive : A1
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	toremifene Sensitive: A1 - Approval toremifene Sensitive : A1
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2
ER positive ER positive	Uterine Corpus Leiomyosarcoma Uterine Corpus Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
ER positive ER positive	Male Breast Cancer Male Breast Cancer	tamoxifen Sensitive: A2 - Guideline tamoxifen Sensitive : A2
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	neratinib Sensitive: A2 - Guideline neratinib Sensitive : A2
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	gimeracil/oteracil/tegafur Sensitive: B - Late Trials gimeracil/oteracil/tegafur Sensitive : B
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	exemestane Sensitive: C1 - Off-label exemestane Sensitive : C1
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant Sensitive: C1 - Off-label fulvestrant Sensitive : C1
ER positive ER positive	Breast Cancer Breast Cancer	capecitabine Sensitive: C2 – Inclusion Criteria capecitabine Sensitive : C2
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	Z-endoxifen hydrochloride Sensitive: C2 – Inclusion Criteria Z-endoxifen hydrochloride Sensitive : C2
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	SAR439859 Sensitive: C2 – Inclusion Criteria SAR439859 Sensitive : C2
ER positive ER positive	Ovarian Cancer Ovarian Cancer	ribociclib Sensitive: C2 – Inclusion Criteria ribociclib Sensitive : C2
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	G1T48 Sensitive: C2 – Inclusion Criteria G1T48 Sensitive : C2
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	capecitabine Sensitive: C2 – Inclusion Criteria capecitabine Sensitive : C2
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	TAK-228 Sensitive: C2 – Inclusion Criteria TAK-228 Sensitive : C2
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	H3B-6545 Sensitive: C2 – Inclusion Criteria H3B-6545 Sensitive : C2
ER positive ER positive	Endometrial Cancer Endometrial Cancer	ribociclib + letrozole Sensitive: C2 – Inclusion Criteria ribociclib + letrozole Sensitive : C2
ER positive ER positive	Breast Cancer Breast Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	AZD9833 Sensitive: C2 – Inclusion Criteria AZD9833 Sensitive : C2

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES